Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | PRKACG | P22612 | 1/20 | 0.38 |
| ▸ | PRKACB | P22694 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21877759 | 1.00 | PRKACA (0.38) | PRKACAPRKACGPRKACBGAAKDM4E | |
| SCHEMBL31278318 | 0.87 | PRKACA (0.46) | PRKACAPRKACGPRKACBGAAKDM4E | |
| SCHEMBL21877621 | 0.78 | JAK2 (0.33) | JAK2JAK1TYK2 | |
| SCHEMBL21877623 | 0.78 | JAK2 (0.33) | JAK2JAK1TYK2 | |
| SCHEMBL20564864 | 0.73 | ALDH1A1 (0.37) | PRKACAPRKACGPRKACBGAAKDM4E | |
| SCHEMBL31278050 | 0.72 | PRKACA (0.39) | PRKACAPRKACGPRKACB | |
| SCHEMBL17447898 | 0.68 | PIK3CD (0.45) | PRKACAPRKACGPRKACBKDM4EALDH1A1 | |
| SCHEMBL17447896 | 0.68 | PIK3CD (0.45) | PRKACAPRKACGPRKACBKDM4EALDH1A1 | |
| SCHEMBL20565555 | 0.67 | HTT (0.46) | KDM4EALDH1A1HPGDJAK2JAK1 | |
| SCHEMBL23630311 | 0.67 | ALDH1A1 (0.43) | PRKACAPRKACGPRKACBGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11026946-B2 | Pharmacologically active alicyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | RICHTER GEDEON NYRT. (HU) | 2021-06-08 | — | — | US | disclosed |
| US-11026946-B2 | Pharmacologically active alicyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | RICHTER GEDEON NYRT. (HU) | 2021-06-08 | — | — | US | disclosed |
| US-20200129515-A1 | Pharmacologically Active Alicyclic-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives | RICHTER GEDEON NYRT. (HU) | 2020-04-30 | — | — | US | disclosed |
| US-20200129515-A1 | Pharmacologically Active Alicyclic-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives | RICHTER GEDEON NYRT. (HU) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129515-A1 | Pharmacologically Active Alicyclic-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives | GABRA5, GABRA1, P2RX5 | PRKACA 945/4885PRKACG 1169/4885PRKACB 1217/4885 |
| US-11026946-B2 | Pharmacologically active alicyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | GABRA5, GABRA1, P2RX5 | PRKACA 945/4885PRKACG 1169/4885PRKACB 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.